BDSX

Biodesix, Inc. is a diagnostic solutions company specializing in advanced blood-based testing to help guide treatment decisions and improve patient outcomes in lung disease, particularly lung cancer. Headquartered in Boulder, Colorado, Biodesix has developed a suite of proprietary diagnostic tests that use sophisticated bioinformatics, machine learning, and proteomic/genomic analysis to provide clinically actionable information for healthcare providers. The company's tests help physicians determine disease risk, select appropriate treatments, monitor treatment response, and detect disease recurrence earlier. Biodesix's key products include the Nodify Lung nodule risk assessment solution, which helps determine the probability that a pulmonary nodule detected on CT scan is benign or malignant, aiding decisions about whether invasive procedures are needed. The company also offers IQLung, a blood test that can help identify the presence of lung cancer, and GeneStrat tumor profiling tests that provide information about specific genomic alterations in lung cancer to guide targeted therapy selection. These tests address critical clinical decision points in the lung cancer patient journey from initial detection through treatment and monitoring. The company operates a CLIA-certified and CAP-accredited clinical laboratory in Boulder where samples are processed. Biodesix has secured reimbursement coverage from major payers for several tests, which is critical for commercial adoption. The company serves pulmonologists, oncologists, thoracic surgeons, and other physicians managing lung disease patients. Biodesix competes in the growing precision medicine and liquid biopsy markets, where blood-based testing is increasingly used to complement or replace tissue biopsies. The company continues to advance its test menu, generate clinical evidence supporting test utility, expand reimbursement coverage, and grow market adoption through physician education and commercial infrastructure.